How to Get Rezdiffra (Resmetirom) in Mississippi

What Is Rezdiffra and Why Does It Matter for Mississippi Patients?

Rezdiffra (resmetirom) is the first FDA-approved oral therapy specifically targeting metabolic dysfunction-associated steatohepatitis, or MASH, with liver fibrosis. The FDA granted accelerated approval in March 2024 based on surrogate histological endpoints from the MAESTRO-NASH trial. Mississippi carries one of the highest burdens of obesity-related liver disease in the United States. The CDC estimates that Mississippi's adult obesity prevalence exceeds 40%, a rate that directly correlates with MASH incidence reported via CDC state-level data.

Before resmetirom, no pharmacotherapy was approved for MASH. Patients relied on weight loss, vitamin E, or off-label pioglitazone. Resmetirom works as a selective thyroid hormone receptor beta (THR-β) agonist, reducing hepatic fat and improving fibrosis markers without the systemic thyroid effects associated with T3 or T4 analogs. In MAESTRO-NASH (N=966), the 80 mg dose achieved MASH resolution without worsening of fibrosis in 25.9% of patients at 52 weeks versus 9.7% on placebo [1]. The 100 mg dose reached 29.9% versus the same placebo rate [1]. Those numbers represent a real treatment option where none existed.

Mississippi has limited hepatology subspecialty access, with most gastroenterologists and hepatologists concentrated in Jackson and the Gulf Coast corridor. Telehealth fills a real gap for patients in the Delta and rural northern counties who may live more than 90 minutes from the nearest liver specialist.

Eligibility: Who Qualifies for Rezdiffra in Mississippi?

The FDA label restricts Rezdiffra to adults with noncirrhotic MASH and moderate to advanced hepatic fibrosis, corresponding to fibrosis stages F1b through F3 on liver biopsy or validated noninvasive assessment [2]. Cirrhotic patients (F4) are excluded from the current indication. Mississippi prescribers must confirm this staging before initiating therapy.

According to the American Association for the Study of Liver Diseases (AASLD) practice guidance, a combination of noninvasive tests can be used for initial risk stratification. A FIB-4 score above 1.3 warrants further evaluation with vibration-controlled transient elastography (FibroScan) or the Enhanced Liver Fibrosis (ELF) panel. A liver stiffness measurement between 8.0 kPa and 13.9 kPa generally corresponds to significant fibrosis (F2 to F3) without cirrhosis.

Liver biopsy remains the gold standard but is not always required if noninvasive tests converge on a consistent fibrosis stage. Most commercial insurers and prior authorization protocols in Mississippi accept FibroScan results combined with elevated ALT and a FIB-4 above 2.67 as sufficient documentation for F3 fibrosis.

Patients should also have a confirmed diagnosis of MASH rather than simple steatosis. The distinction matters clinically and for payer purposes. A hepatic fat fraction above 5% on MRI-PDFF, paired with elevated aminotransferases and metabolic risk factors (type 2 diabetes, BMI above 30, dyslipidemia), supports the MASH diagnosis when biopsy is deferred.

Required Labs Before Starting Rezdiffra in Mississippi

Prescribers in Mississippi will order a specific set of baseline labs before writing a Rezdiffra prescription. These labs serve both clinical and prior authorization purposes.

Hepatic panel and fibrosis assessment: AST, ALT, GGT, total bilirubin, albumin, platelet count, and INR. These values feed into the FIB-4 calculation (age × AST / platelets × √ALT). A National Institutes of Health summary of noninvasive fibrosis markers notes that FIB-4 is the recommended first-line screening tool in primary care settings.

Thyroid function: TSH and free T4 at baseline. Resmetirom is a THR-β agonist, and while it does not significantly alter systemic thyroid hormone levels at approved doses, the FDA label recommends thyroid monitoring. Patients with uncontrolled hypothyroidism or hyperthyroidism should achieve stable thyroid function before initiation [2].

Lipid panel: Resmetirom reduces LDL cholesterol, a secondary benefit observed in MAESTRO-NASH. At 52 weeks, LDL dropped by approximately 14% in the 80 mg group compared to placebo [1]. Baseline lipids help track this response and may inform whether concurrent statin therapy can be adjusted.

Metabolic markers: Hemoglobin A1c and fasting glucose, particularly because a significant proportion of MASH patients have concurrent type 2 diabetes. In MAESTRO-NASH, roughly 60% of participants had diabetes at enrollment [1].

Most Mississippi laboratories, including Quest and Labcorp draw stations in Jackson, Hattiesburg, Tupelo, and Biloxi, can process the full panel. Telehealth providers typically send lab orders to the patient's nearest draw site.

Telehealth Access to Rezdiffra in Mississippi

Mississippi permits telehealth prescribing for medications like Rezdiffra under the Mississippi Telehealth Act. A provider-patient relationship can be established via synchronous video visit, meaning patients in rural counties do not need to travel to Jackson for an in-person hepatology consult to receive a prescription.

Telehealth prescribing for Rezdiffra in Mississippi works. Several national liver disease telehealth platforms and GI-focused practices accept Mississippi patients. The prescriber must hold an active Mississippi medical license or practice under a recognized interstate compact.

A typical telehealth pathway looks like this: the patient completes an intake form documenting metabolic history, uploads recent labs (or receives a new lab order), and attends a video consultation. If the prescriber confirms MASH with qualifying fibrosis, the prescription is sent electronically to a specialty or 503A pharmacy.

Dr. Zobair Younossi, chairman of the Global NASH Council, has noted that "telehealth is removing geographic barriers to NASH care, particularly in states where hepatology is concentrated in a single metropolitan area" quoted in the Journal of Hepatology, 2023. This observation is directly applicable to Mississippi, where hepatology subspecialty clinics are sparse outside Jackson.

One consideration: some insurers require the prescribing provider to be a hepatologist, gastroenterologist, or endocrinologist for prior authorization approval. A primary care physician or NP may need to document a specialist referral or collaborative note to satisfy these payer requirements.

Who Can Prescribe Rezdiffra in Mississippi?

Any physician (MD or DO) with an active Mississippi license and a valid DEA registration can prescribe Rezdiffra. The drug is not a controlled substance, so no special DEA scheduling applies.

Nurse practitioners in Mississippi prescribe under a collaborative practice agreement with a physician, as outlined by the Mississippi Board of Nursing. An NP can prescribe Rezdiffra if the collaborative agreement covers hepatic or metabolic conditions and the supervising physician approves the prescribing scope.

Physician assistants in Mississippi prescribe under supervising physician delegation. The PA's prescriptive authority depends on the scope defined in the supervisory agreement filed with the Mississippi State Board of Medical Licensure.

In practice, most Rezdiffra prescriptions originate from gastroenterologists, hepatologists, or endocrinologists because payer prior authorization pathways tend to favor specialty prescribers. A primary care prescriber can initiate the process but may face additional documentation hurdles.

Pharmacy Access and 503A Compounding in Mississippi

Rezdiffra is manufactured by Madrigal Pharmaceuticals and distributed through specialty pharmacy channels. The brand-name product is available as 60 mg, 80 mg, and 100 mg oral tablets [2].

Mississippi licenses 503A compounding pharmacies that can prepare and dispense prescription medications, including resmetirom formulations, under a valid patient-specific prescription. The FDA's compounding framework under section 503A of the FD&C Act allows state-licensed pharmacies to compound drugs for individual patients when a prescriber determines a clinical need. These pharmacies can ship within Mississippi and, depending on their licensure, across state lines.

Patients filling Rezdiffra at a specialty pharmacy should expect the following process: the prescription is received electronically, the pharmacy initiates a benefits investigation, prior authorization is submitted (if not already completed), and the medication ships directly to the patient or is available for pickup. Turnaround from prescription to delivery typically ranges from 7 to 20 business days, depending on the payer's prior authorization timeline.

For patients paying out of pocket or using 503A pharmacies, the process may be faster because no insurance adjudication is required. Madrigal Pharmaceuticals offers a copay assistance program for commercially insured patients that can reduce out-of-pocket costs to as low as $0 for eligible individuals per the manufacturer's patient support program.

Prior Authorization for Rezdiffra in Mississippi

Mississippi Medicaid does not currently cover Rezdiffra. Patients on Medicaid will need to explore alternative coverage pathways, including manufacturer patient assistance programs or appeals.

For commercial insurance, prior authorization is standard. The documentation package typically includes:

Clinical documentation: confirmed MASH diagnosis with supporting labs (elevated ALT, hepatic steatosis on imaging), fibrosis staging via biopsy or noninvasive testing (FibroScan with liver stiffness measurement, FIB-4 score, or ELF panel), and metabolic comorbidity documentation (BMI, A1c, lipid panel).

Prescriber credentials: some plans require the prescriber to be a board-certified hepatologist or gastroenterologist. If the prescriber is a PCP, NP, or PA, a specialist consultation note may be required.

Step therapy documentation: certain plans require documentation that the patient has attempted lifestyle modification (diet and exercise) for a defined period, typically 6 to 12 months, and that weight loss alone has not resolved hepatic fibrosis. The AASLD and American Gastroenterological Association joint guidance recommends pharmacotherapy when lifestyle intervention has not achieved histological improvement.

Failure or contraindication to alternatives: while no other FDA-approved MASH drug existed before resmetirom, some insurers may require documentation that vitamin E or pioglitazone was tried and either failed or was contraindicated (e.g., pioglitazone is contraindicated in heart failure, and vitamin E carries concerns in patients with prostate cancer risk).

The prior authorization review cycle for Mississippi commercial plans (Blue Cross Blue Shield of Mississippi, UnitedHealthcare, Aetna, Cigna) typically takes 5 to 15 business days. If denied, a peer-to-peer review with the medical director can be requested within 30 days.

Cost and Financial Assistance for Rezdiffra in Mississippi

The wholesale acquisition cost (WAC) for Rezdiffra is approximately $47,400 per year at the 80 mg or 100 mg dose. This figure reflects the list price before insurance negotiation, rebates, or copay assistance.

Mississippi patients with commercial insurance who receive prior authorization approval may pay significantly less. Madrigal's copay card program, branded as RezdiffrAssist, covers eligible commercially insured patients and can reduce copays to $0 per fill per the manufacturer's support program.

Uninsured patients or those on Mississippi Medicaid (where Rezdiffra is not covered) may qualify for Madrigal's patient assistance program, which provides the medication at no cost to income-eligible individuals. Eligibility criteria typically include household income at or below 400% of the federal poverty level.

503A compounded resmetirom may be available at lower cost in some cases, though pricing varies by pharmacy. Patients should verify with their prescriber that the compounded formulation meets quality and bioequivalence standards.

MAESTRO-NASH Trial Results: The Evidence Behind the Approval

The FDA's accelerated approval of Rezdiffra rested on histological endpoints from the MAESTRO-NASH phase 3 trial, published in the New England Journal of Medicine in February 2024 [1]. The trial enrolled 966 adults with biopsy-confirmed MASH and fibrosis stages F1b through F3.

At 52 weeks, MASH resolution without fibrosis worsening occurred in 25.9% of the 80 mg group and 29.9% of the 100 mg group, compared to 9.7% with placebo. Fibrosis improvement by at least one stage without MASH worsening occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% on placebo [1].

The AASLD has described resmetirom as "a meaningful advance for patients with MASH who previously had no approved pharmacotherapy" per AASLD public statement on MAESTRO-NASH results.

Secondary endpoints showed LDL cholesterol reduction of approximately 14% (80 mg) and 18% (100 mg), triglyceride reduction, and decreases in liver enzyme levels. These cardiometabolic benefits are relevant for Mississippi's population, where cardiovascular disease and metabolic syndrome prevalence are among the highest nationally per CDC chronic disease data.

Adverse events were generally mild. The most common side effects were diarrhea (occurring in approximately 27% of the 100 mg group vs. 16% placebo) and nausea. Serious hepatic events were rare, and discontinuation rates due to adverse events were similar between active and placebo arms [1].

Monitoring After Starting Rezdiffra in Mississippi

Once a Mississippi patient begins Rezdiffra, ongoing monitoring follows both the FDA label and clinical best practice. Liver function tests (AST, ALT, bilirubin) should be checked at baseline, then every 3 months for the first year, and every 6 months thereafter [2]. Thyroid function (TSH) should be reassessed at 3 months and then annually.

Prescribers should also repeat FibroScan or other noninvasive fibrosis assessments at 12 months to evaluate treatment response. The FDA's continued approval of Rezdiffra depends on confirmatory trials demonstrating clinical outcomes (e.g., reduced progression to cirrhosis), so ongoing response monitoring is both clinically and regulatorily relevant.

Patients experiencing persistent diarrhea, significant nausea, or new thyroid symptoms should contact their prescriber promptly. Dose adjustment from 100 mg to 80 mg may be considered if gastrointestinal side effects are limiting.

Rezdiffra 80 mg is the recommended starting dose, with escalation to 100 mg based on body weight (patients weighing <100 kg start at 80 mg; those weighing ≥100 kg start at 100 mg) [2].